Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.71 USD | -2.47% | +0.68% | +25.66% |
Jun. 04 | Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating | MT |
Jun. 03 | Transcript : Crinetics Pharmaceuticals, Inc. - Special Call |
Evolution of the average Target Price on Crinetics Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Crinetics Pharmaceuticals, Inc.
Oppenheimer | |
Morgan Stanley | |
Piper Sandler | |
HC Wainwright | |
JonesTrading Institutional Services | |
JMP Securities | |
Citigroup | |
Cantor Fitzgerald | |
Baird | |
Evercore ISI | |
LifeSci Capital | |
SVB Securities LLC | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- CRNX Stock
- Consensus Crinetics Pharmaceuticals, Inc.